OBI Pharma, Inc. was informed by the patent office that patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions And Uses Thereof has been granted by United States Patent and Trademark Office under the patent number 15/662,162. OBI-866 is an active immunotherapeutic cancer vaccine targeting SSEA-4, conjugating SSEA-4 and carrier protein KLH and triggers immune responses against hard-to-treat cancers once injected into the human system. OBI-866 has been granted by TFDA to proceed to Phase I human clinical study and is now open for enrollment actively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
61.3 TWD | +0.16% | 0.00% | -11.67% |
1st Jan change | Capi. | |
---|---|---|
-11.67% | 433M | |
+30.12% | 48.16B | |
-0.82% | 41.73B | |
+42.66% | 41.03B | |
-5.26% | 28.77B | |
+10.15% | 25.59B | |
-22.65% | 18.96B | |
+9.12% | 12.92B | |
+29.25% | 12.03B | |
-1.98% | 11.77B |
- Stock Market
- Equities
- 4174 Stock
- News OBI Pharma, Inc.
- United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof